Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05168800
Other study ID # STUDY00032340
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 21, 2022
Est. completion date July 21, 2023

Study information

Verified date August 2023
Source Dartmouth-Hitchcock Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CONFIDENT Study is an online three-arm randomized trial that aims to help long-term care workers in the United States feel more confident about the Coronavirus Disease 2019 (COVID-19) vaccines. The study will compare two different interventions to usual online information (website of the Centers for Disease Control and Prevention). The first intervention is a Dialogue-Based Webinar where people can interact and ask questions about the vaccines. The second intervention is a Social Media Website that will feature curated content about the vaccines from popular social media platforms. Participants will be asked to completed four online surveys. The first survey will be completed pre-intervention and immediately upon study enrollment (Time 0). Participants will be randomized to a trial arm at the end of the Time 0 survey. Intervention follow-up surveys will be completed 3 weeks post-randomization (Time 1), three months post-randomization (Time 2), and 6 months post-randomization (Time 3).


Recruitment information / eligibility

Status Completed
Enrollment 2634
Est. completion date July 21, 2023
Est. primary completion date February 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - at least 18 years of age - can read, write, and understand English - lives in the United States - has worked in a long-term care setting in the past two years - can provide information to confirm they have worked in a long-term care setting - is not pregnant or breastfeeding - at least somewhat worried about the COVID-19 vaccines and/or has not received a COVID-19 vaccine booster shot Exclusion Criteria: - under 18 years of age - cannot read, write, and understand English - does not live in the United States - has not worked in a long-term care setting in the past two years - cannot provide information to confirm they have worked in a long-term care setting - is pregnant or breastfeeding - less than somewhat worried about the COVID-19 vaccines and has received at least one COVID-19 vaccine booster shot

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dialogue-Based Webinar
One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
Social Media Website
A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
Other:
Enhanced Usual Practice
COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.

Locations

Country Name City State
United States Dartmouth College Lebanon New Hampshire

Sponsors (5)

Lead Sponsor Collaborator
Dartmouth-Hitchcock Medical Center East Carolina University, Institute for Healthcare Improvement, National Association of Health Care Assistants, Patient-Centered Outcomes Research Institute

Country where clinical trial is conducted

United States, 

References & Publications (1)

Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016 Oct;12:295-301. doi: 10.1016/j.ebiom.2016.08.042. Epub 2016 Sep 13. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Dialogue-Based Webinar exposure Participants' exposure to the Dialogue-Based Webinar intervention assessed via webinar attendance data. Time of individual participants' exposure to intervention
Other Social Media Website exposure Participants' exposure to the Social Media Website intervention assessed via website visit data. Time of individual participants' exposure to intervention
Other Dialogue-Based Webinar acceptability Likelihood of recommending the Dialogue-Based Webinar intervention to a coworker, assessed using a single-item adapted Net Promoter Score item. 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2)
Other Social Media Website acceptability Likelihood of recommending the Social Media Website intervention to a coworker, assessed using a single-item adapted Net Promoter Score item. 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2)
Other Enhanced Usual Practice acceptability Likelihood of recommending the Centers for Disease Control and Prevention (CDC) website to a coworker, assessed using a single-item adapted Net Promoter Score item. 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2)
Primary COVID-19 vaccine confidence Confidence in the COVID-19 vaccines, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. 3 weeks post-randomization (Time 1)
Secondary Change from baseline in COVID-19 vaccine confidence Change in confidence in the COVID-19 vaccines from baseline, assessed using the 3-item Vaccine Confidence Index adapted for COVID-19. Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
Secondary Likelihood of recommending COVID-19 vaccination Likelihood of recommending COVID-19 vaccination to someone who is not vaccinated, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). 3 weeks post-randomization (Time 1)
Secondary Likelihood of recommending COVID-19 booster vaccination to coworker Likelihood of recommending COVID-19 booster vaccination to a coworker, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine uptake (any dose) Receipt of any does of a COVID-19 vaccine, assessed using a single item with multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine uptake (initial series completion) Completion of initial COVID-19 vaccine series, assessed using two items with multiple choice (single answer) formats. 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine uptake (booster completion) Receipt of a COVID-19 booster vaccine if initial series completed, assessed using a single item with multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine intent (initial series) Intent to get a COVID-19 vaccine if unvaccinated, assessed using a single item with multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine intent (booster) Intent to get a COVID-19 booster vaccine if not yet received, assessed using a single item with multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary COVID-19 vaccine intent (future vaccine recommendations) Intent to get COVID-19 vaccines regularly in the future if they are recommended, assessed using a single item with multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary Feeling informed about the COVID-19 vaccines Extent of feeling informed (having enough information and understanding that information) about the COVID-19 vaccines, using two self-developed items. Each item is assessed on a 5-point scale ranging from 0 ('No at all confident') to 4 ('Very confident'). 3 weeks post-randomization (Time 1)
Secondary Identification of COVID-19 vaccine information and misinformation Identification of COVID-19 vaccine information and misinformation, assessed using four items. Some items self-developed and some adapted from Hamel et al., 2021 (see https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-media-and-misinformation/). Each item is assessed using a multiple choice (single answer) format. 3 weeks post-randomization (Time 1)
Secondary Trust in COVID-19 vaccine information from different sources Trust in COVID-19 vaccine information given by different people and organizations, assessed using a list of three different sources. Each source is assessed using a 4-point scale ranging from 0 ('Not at all') to 3 ('A lot'). 3 weeks post-randomization (Time 1)
Secondary Change from baseline in secondary outcomes Change in secondary outcomes from baseline, assessed using the same measures identified in Outcomes 3-13. Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
Secondary As-treated analyses of primary and secondary outcomes All primary and secondary outcomes assessed only for those who were exposed to their relevant study intervention and/or refresher intervention. Baseline (Time 0); 3 weeks post-randomization (Time 1); 3 months post-randomization (Time 2); 6 months post-randomization (Time 3)
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure